Physiogenex is a leading preclinical research organization (CRO) specializing in metabolic disorders such as diabetes, insulin resistance, obesity, fatty liver (NASH / NAFLD), dyslipidemia, atherosclerosis and cardiovascular complications. We provide: - Classical and proprietary diet-induced in vivo models - Innovative in-house techniques (RCT) and gold standard methods (glucose clamps with radiolabelled tracers, …) - In vivo preclinical imaging services Our models and technologies are customized and we deliver unparalleled scientific expertise for R&D, preclinical development, post-marketing studies and drug repositioning. We provide both the biopharmaceutical and nutraceutical companies with optimal and reliable solutions for successful strategic decision-making.
Looking for a particular Physiogenex employee's phone or email?
The Physiogenex annual revenue was $5 million in 2026.
Thierry Sulpice is the Founder, Chairman, CEO and CSO of Physiogenex.
23 people are employed at Physiogenex.
Physiogenex is based in Escalquens, Occitania.
The NAICS codes for Physiogenex are [54, 5417, 541713, 541, 54171].
The SIC codes for Physiogenex are [873, 87].